Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Methotrexate Cmax" refers specifically to the maximum observed plasma concentration of the drug methotrexate following administration. This value is used in clinical pharmacology studies to compare different formulations or routes of administration—such as subcutaneous versus intramuscular injection—and assess bioequivalence between products. It reflects how much of the drug reaches systemic circulation at its peak but does not represent any molecular target or biological structure. Therefore, it should not be listed among molecular targets like enzymes or receptors.
Not applicable for "Cmax". For reference: Methotrexate acts primarily by inhibiting dihydrofolate reductase and interfering with DNA synthesis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methotrexate Cmax.